- Home
- BNGO
BNGO
Bionano Genomics Inc.
as 07-26-2024 4:00pm EST
| Founded: | 2003 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | N/A | IPO Year: | 2018 |
| Target Price: | $4.00 | AVG Volume (30 days): | 2.1M |
| Analyst Decision: | Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.02 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.52 - $6.20 | Next Earning Date: | 08-07-2024 |
| Revenue: | $37,470,000 | Revenue Growth: | 26.93% |
| Revenue Growth (this year): | 7.56% | Revenue Growth (next year): | 24.33% |
Latest Bionano Genomics Inc. News
BNGO Breaking Stock News: Dive into BNGO Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
Bionano Announces Publication of First Multi-Site Study to Analyze the Utility of OGM in Multiple Myeloma
MT Newswires
18 days ago
Bionano Genomics Raises $10 Million From Direct Offering
GlobeNewswire
18 days ago
Bionano Announces Closing of up to $30 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
MT Newswires
21 days ago
Bionano Genomics to Sell Shares in Direct Offering
GlobeNewswire
22 days ago
Bionano Announces up to $30 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
GlobeNewswire
25 days ago
Bionano Announces Presentation of OGM Utility Across Stem Cell Therapy Applications at the International Society for Stem Cell Research (ISSCR) Annual Meeting
MT Newswires
a month ago
Bionano Genomics Says Revvity to Commercialize VIA Software
GlobeNewswire
a month ago
Bionano Announces Software Marketing Agreement with Revvity for Newborn Sequencing Research
Compare BNGO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BNGO Bionano Genomics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.